PeriphaGen is a biopharmaceutical company focused on peripheral nerve gene therapy and committed to the development of innovative products for difficult-to-treat neurological disorders thereby improving patients' quality of life. We believe that the best way to treat the nervous system diseases is to directly target neurons. Our proprietary Neuronal Therapeutics (NET) platform can express gene constructs in discrete regions of the nervous system following a simple intradermal injection, allowing for unparalleled treatment specificity and substantially reduced systemic adverse effects. Our lead product, PGN-503, is focused on protecting against Chemotherapy Induced Peripheral Neuropathy (CIPN), the leading dose-limiting side effect observed in the majority of antineoplastic drugs. Our pipeline also includes the treatment of chronic pain by NET drugs designed to block multiple pain pathways through the expression of various gene combinations.